Showing results (1971-1980 of 2,029) with videos related to
Sort By:
Pageof 203
Leukemia|April 14, 2021
Targeted gene panels identify a high frequency of pathogenic germline variants in patients diagnosed with a hematological malignancy and at least one other independent cancerDeepak Singhal, Christopher N Hahn, Simone Feurstein, et al.Science Translational Medicine|March 20, 2024
Apelin stimulation of the vascular skeletal muscle stem cell niche enhances endogenous repair in dystrophic miceEmmeran Le Moal, Yuguo Liu, Jasmin Collerette-Tremblay, et al.Medrxiv : the Preprint Server for Health Sciences|March 18, 2024
Coronary Microvascular Function Following Severe PreeclampsiaMichael C Honigberg, Katherine E Economy, Maria A Pabón, et al.Hypertension (Dallas, Tex. : 1979)|April 2, 2024
Coronary Microvascular Function Following Severe PreeclampsiaMichael C Honigberg, Katherine E Economy, Maria A Pabón, et al.Environmental Health Perspectives|October 13, 2006
Saxitoxin puffer fish poisoning in the United States, with the first report of Pyrodinium bahamense as the putative toxin sourceJan H Landsberg, Sherwood Hall, Jan N Johannessen, et al.Leukemia|May 16, 2019
The mutational burden of therapy-related myeloid neoplasms is similar to primary myelodysplastic syndrome but has a distinctive distributionDeepak Singhal, Li Yan A Wee, Monika M Kutyna, et al.Blood Advances|November 8, 2019
Genome editing of HBG1 and HBG2 to induce fetal hemoglobinJean-Yves Métais, Phillip A Doerfler, Thiyagaraj Mayuranathan, et al.ACS Chemical Biology|June 20, 2025
Discovery and Validation of a Novel Class of Necroptosis Inhibitors Targeting RIPK1Lior Soday, Chotima Seripracharat, Janine L Gray, et al.Journal of Medicinal Chemistry|November 28, 2017
Discovery and Optimization of Pyrrolopyrimidine Inhibitors of Interleukin-1 Receptor Associated Kinase 4 (IRAK4) for the Treatment of Mutant MYD88L265P Diffuse Large B-Cell LymphomaJames S Scott, Sébastien L Degorce, Rana Anjum, et al.Cancer Research|September 14, 2021
Oxidative Phosphorylation Is a Metabolic Vulnerability in Chemotherapy-Resistant Triple-Negative Breast CancerKurt W Evans, Erkan Yuca, Stephen S Scott, et al.Pageof 203